Multiple Sclerosis

To determine whether newly developed treatments are safe and effective, physician-scientists rely on clinical trials. These studies are not only important research tools; they also provide patients with access to experimental therapies not yet widely available.

Because technologies and therapeutic options are continually developing, the OMRF Multiple Sclerosis Center uses clinical trials as one way of delivering cutting-edge treatments to our patients. Of course, participating in clinical trials is optional. But many choose to enroll to receive new therapies and improve standards of care for individuals with MS. Patients also receive medication, laboratory and diagnostic procedures, and intensive medical evaluation and assessment—all at no cost.

Patients may also participate in our MS Center Registry and Repository. This unique research tool allows individuals with MS to provide clinical information and samples to help our physician-scientists better understand this complicated disease.

Clinical research is proving that with comprehensive disease management, we can impact the course of the disease, achieve normal or near-normal life expectancy, reduce the potential for significant disability, and improve quality of life.

For more information on any of our studies, call (405) 271-6241 or email Micki-Drake@omrf.org or Kellie-Kraus@omrf.org.

Currently Enrolling

Exploring the Safety and Tolerability of Conversion From Oral, Injectable or Infusion Disease Modifying Therapies to Dose-Titrated Oral Siponimod (Mayzent®) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-Month Open Label, Multicenter Phase IIIb Study (EXCHANGE),” Protocol CBAF312AUS02

A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes In Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063),” Protocol RPC-1063-MS-001 Enlighten

A Phase 3, Randomized, Double-Blind Efficacy and Safety Study Comparing SAR442168 to teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis (GEMINI 1),” Protocol EFC16033

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety,” Protocol MS200527_0080 Evolution

A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes in Patients with Relapsing Multiple Sclerosis Transitioning from Dimethyl fumarate or Fingolimod Therapy,” Protocol COMB157G23101 ARTIOS

A phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with Teriflunomide in adult patients with RRMS. GN41851  Fenhance

Cladribine Tablets: Collaborative Study to Evaluate the Impact On Central Nervous System Biomarkers in Multiple Sclerosis (CLOCK-MS)